Business Wire | Aug 3, 2021 04:02PM EDT

Personalis to Participate at the 6th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

Aug. 03, 2021

MENLO PARK, Calif.--(BUSINESS WIRE)--Aug. 03, 2021--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the 6th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 17, 2021.

About Personalis, Inc.

Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the VA MVP. In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The Personalis(r) ImmunoID NeXT Platform(r) is designed to adapt to the complex and evolving understanding of cancer, providing Personalis' biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis' Clinical Laboratory is GxP aligned as well as CLIA'88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

View source version on businesswire.com: https://www.businesswire.com/news/home/20210803005158/en/

CONTACT: Investor Relations Contact: Caroline Corner investors@personalis.com www.westwickepartners.com 415-202-5678

CONTACT: Media Contact: Jennifer Havlek pr@personalis.com www.personalis.com 650-752-1300